Pfenex, Inc
Primrose Bio, Inc. is a biotechnology company founded in 2023 through the merger of Pelican Technology Holdings and Primordial Genetics. It specializes in developing high-efficiency production systems for complex biologics, leveraging advanced protein expression and enzyme engineering technologies. The company's mission is to create innovative solutions and tools for essential biotherapeutics, vaccines, and biologics, aiming for positive health and environmental impact. Primrose Bio's vision is to enable the discovery and production of new biological molecules and cells with unprecedented productivity and accessibility, supporting the next generation of therapeutics and vaccines.
Industries
Nr. of Employees
small (1-50)
Pfenex, Inc
Patents
Products
Engineered RNA polymerases for mRNA manufacturing
Engineered polymerases designed for high-yield, long-template mRNA synthesis with flexibility for 5' cap incorporation to improve mRNA drug-substance quality and manufacturing economics.
Commercial CRM197 carrier protein (research to GMP grades)
Ultra-pure CRM197 carrier protein supplied in multiple quantities and quality grades for conjugate vaccine development and manufacture, offered with supply-chain and regulatory support.
Production strain licensing
Licenses for engineered production strains and platform access with flexible commercial terms, including royalty and royalty-free options to enable partner-led manufacturing.
Engineered RNA polymerases for mRNA manufacturing
Engineered polymerases designed for high-yield, long-template mRNA synthesis with flexibility for 5' cap incorporation to improve mRNA drug-substance quality and manufacturing economics.
Commercial CRM197 carrier protein (research to GMP grades)
Ultra-pure CRM197 carrier protein supplied in multiple quantities and quality grades for conjugate vaccine development and manufacture, offered with supply-chain and regulatory support.
Production strain licensing
Licenses for engineered production strains and platform access with flexible commercial terms, including royalty and royalty-free options to enable partner-led manufacturing.
Services
Short-term laboratory feasibility assessment using pooled cloning, high-throughput expression screening, basic analytics, and a deliverable report to inform next steps in strain and process development.
Automated strain engineering, screening, and 2 L DOE-based fermentation optimization to identify lead production strains and establish parameters for scale-up and tech transfer.
Generation of large combinatorial gene libraries and phenotypic screening to discover novel enzymes, improved protein variants, or host strains with enhanced production traits.
Biological oligonucleotide manufacturing process development using engineered polymerases to offer a sustainable and cost-effective alternative to chemical synthesis.
In-house analytical support for titer, purity and activity testing using methods such as SDS-CGE, ELISA, BLI, HPLC, LC-MS and peptide mapping.
Short-term laboratory feasibility assessment using pooled cloning, high-throughput expression screening, basic analytics, and a deliverable report to inform next steps in strain and process development.
Automated strain engineering, screening, and 2 L DOE-based fermentation optimization to identify lead production strains and establish parameters for scale-up and tech transfer.
Generation of large combinatorial gene libraries and phenotypic screening to discover novel enzymes, improved protein variants, or host strains with enhanced production traits.
Biological oligonucleotide manufacturing process development using engineered polymerases to offer a sustainable and cost-effective alternative to chemical synthesis.
In-house analytical support for titer, purity and activity testing using methods such as SDS-CGE, ELISA, BLI, HPLC, LC-MS and peptide mapping.
Expertise Areas
- Protein expression and strain engineering
- High-throughput library generation and screening
- Enzyme engineering for nucleic acid manufacturing
- Enzymatic oligonucleotide synthesis
Key Technologies
- Pseudomonas fluorescens-based prokaryotic expression
- Automated high-throughput strain screening (96/384 formats)
- Combinatorial gene library generation (genome-wide recombination)
- Engineered RNA polymerases for long-template mRNA synthesis
News & Updates
Primrose Bio announced the launch of Prima RNApols™ for improved long-template mRNA manufacturing, offering higher quality and lower costs.
Primrose Bio announced a collaboration with Serum Institute of India to develop a multi-antigen vaccine.
Primrose Bio and ExPLoRNA Therapeutics announced a strategic partnership to advance mRNA technologies and therapeutics.
Primrose Bio announced a significant investment from 1315 Capital to support the development of manufacturing solutions for next-generation therapeutics.
Ligand signed a purchase and sale agreement with Primrose Bio and made an investment of $15m, aiming to enhance biologic vaccine and therapeutic manufacturing.
FDA approval of Teriparatide Injection
The first product developed using Pfenex Expression Technology® to receive FDA approval, launched in June 2020 by Alvogen.
Primrose Bio announced the launch of Prima RNApols™ for improved long-template mRNA manufacturing, offering higher quality and lower costs.
Primrose Bio announced a collaboration with Serum Institute of India to develop a multi-antigen vaccine.
Primrose Bio and ExPLoRNA Therapeutics announced a strategic partnership to advance mRNA technologies and therapeutics.
Primrose Bio announced a significant investment from 1315 Capital to support the development of manufacturing solutions for next-generation therapeutics.
Ligand signed a purchase and sale agreement with Primrose Bio and made an investment of $15m, aiming to enhance biologic vaccine and therapeutic manufacturing.
FDA approval of Teriparatide Injection
The first product developed using Pfenex Expression Technology® to receive FDA approval, launched in June 2020 by Alvogen.